ArticleJournal, genetic engineering & biotechnology2025
Whole exon screening of SLC2A4 gene and the association of rs5435 with type 2 diabetes in a Bangladeshi case-control study.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes (T2D) is a multifaceted disease influenced by both genetic and environmental factors, posing significant global health challenges. Polymorphisms in the SLC2A4 gene encoding the glucose transporter 4 (GLUT4), have been linked to insulin resistance and T2D. This study, therefore, aims to identify and analyze genetic variants within the SLC2A4 gene and determine their association with T2D risk through a Bangladeshi case-control study. A total of 239 individuals were enrolled in the study, including 127 T2D patients and 112 controls. All 11 exons of the SLC2A4 gene were sequenced in 20 individuals. Exons 2, 3, 4, and 5 of GLUT4 were then sequenced in an additional 99 participants. For the remaining 120 participants, a TaqMan probe-based RT-PCR was conducted to genotype rs5435. Four genetic variants were initially identified, including one synonymous variant (rs5435) in exon 4. There was no significant difference in the allele frequency of the wild-type allele T and variant allele C between the two groups (OR: 1.31, p = 0.13). Genotypic distribution revealed that individuals who were either heterozygous or homozygous for the variant allele are at an increased risk for developing T2D compared to those who are homozygous for the non-risk allele (p = 0.042), suggesting that the SNP could be considered to have a dominant effect on the likelihood of developing T2D. Additionally, in silico analysis revealed that the rs5435 variant introduces an additional loop in the mRNA secondary structure, which is energetically less stable and therefore may interfere with the protein's biological function and play a role in the pathogenesis of T2D. However, further studies with larger cohorts are necessary to validate the impact of rs5435 on the risk of T2D in our population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.